SCHEMBL4425283

SCHEMBL4425283

COc1cccc(CN2CC3C(C2)C3C(=O)Nc2ccc(N3CCOCC3)c(F)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 1/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
WDR5 P61964 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
FAAH O00519 1/20 0.45
ALDH1A1 P00352 3/20 0.45
HPGD P15428 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TSHR P16473 1/20 0.45
MTOR P42345 1/20 0.44
KMT2A Q03164 1/20 0.44
F10 P00742 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414134 0.91 ALDH1A1 (0.49) MAPTKDM4ENPC1RAB9AL3MBTL1
SCHEMBL4415238 0.91 HIF1A (0.52) MAPTKDM4EPOLBNPC1RAB9A
SCHEMBL4415853 0.90 FAAH (0.48) MAPTPOLBNPC1RAB9AL3MBTL1
SCHEMBL4412000 0.90 ABL1 (0.52) MAPTNPC1RAB9AL3MBTL1KMT2A
SCHEMBL2167688 0.89 L3MBTL1 (0.48) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4423658 0.86 NPC1 (0.50) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL4421533 0.86 MTOR (0.49) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4413542 0.85 MCHR1 (0.55) MAPTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL2170675 0.84 L3MBTL1 (0.52) MAPTKDM4EPOLBNPC1RAB9A
SCHEMBL4412368 0.84 MAPT (0.53) MAPTKDM4ENPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP claimed
EP-1680124-A4 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2009-05-13 EP claimed
JP-2007508374-A 2007-04-05 JP claimed
EP-1680124-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS Pfizer Products Incorporated (US) 2006-07-19 EP claimed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US claimed
WO-2005037216-A2 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PRODUCTS INC. (US) 2005-04-28 WO claimed
EP-1680124-B1 BICYCLIC [3.1.0] DERIVATIVES AS GLYCINE TRANSPORTER INHIBITORS PFIZER PROD INC (US) 2017-05-31 EP disclosed
US-7473787-B2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC (US) 2009-01-06 US disclosed
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors PFIZER INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096375-A1 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors SLC6A5, SLC1A5, SLC6A3 MAPT 1368/4885KDM4E 2032/4885POLB 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.